Phase 1/2 study of epacadostat in combination with ipilimumab in patients with unresectable or metastatic melanoma

BACKGROUND: Epacadostat is a potent inhibitor of the immunosuppressive indoleamine 2,3-dioxygenase 1 (IDO1) enzyme. We present phase 1 results from a phase 1/2 clinical study of epacadostat in combination with ipilimumab, an anti-cytotoxic T-lymphocyte-associated protein 4 antibody, in advanced mela...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:J Immunother Cancer
Prif Awduron: Gibney, Geoffrey T., Hamid, Omid, Lutzky, Jose, Olszanski, Anthony J., Mitchell, Tara C., Gajewski, Thomas F., Chmielowski, Bartosz, Hanks, Brent A., Zhao, Yufan, Newton, Robert C., Maleski, Janet, Leopold, Lance, Weber, Jeffrey S.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: BioMed Central 2019
Pynciau:
Research Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC6425606/
https://ncbi.nlm.nih.gov/pubmed/30894212
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40425-019-0562-8
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg